Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

Targeting triple negative BREAst cancer metabolism with a combination of chemotherapy and a diet mimicking FASTing plus/minus metformin in t… Ended

2023-508920-37-00 Triple negative breast cancer 4 2020-05-20
Study of U3-1402 in subjects with non-small cell lung cancer Ended

2024-511205-33-00 METASTATIC OR UNRESECTABLE NON-SMALL CELL LUNG CANCER 3 2020-05-18
Phase III Study of Capivasertib + Fulvestrant vs Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2… Ended

2023-505042-25-00 Locally advanced (inoperable) or metastatic HR+/HER2 br 5 2020-05-05
A Phase 1/2 Study on the effects of the LOXO-292 (study drug) in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tu… Ended

2023-507703-63-00 Pediatric Patients with Advanced RET-Altered Solid or P 9 2020-05-04
Utility of analysis in blood of the evolution of the drug brigatinib for patients with lung cancer with ALK mutations Ended

2024-511317-38-00 ALK+ non-small cell lung cancer 4 2020-05-04
A trial to learn how camizestrant (AZD9833) works compared to fulvestrant and how safe it is in women with advanced breast cancer who have g… Ended

2023-504974-40-00 Estrogen Receptor Positive HER2 Negative Advanced Breas 4 2020-04-24
A study of NY-ESO-1 T-cells (GSK3377794) in synovial sarcoma and myxoid/round cell liposarcoma patients Ended

2024-513032-14-00 Synovial sarcoma and Myxoid/Round Cell Liposarcoma (MRC 4 2020-04-21
A randomized, 2-arm non-comparative phase II study on the efficacy of atezolizumab and Roche bevacizumab (Atezo/Bev) followed by on-demand s… Ended

2024-512682-14-00 Non-resectable hepatocellular carcinoma (HCC) 4 2020-04-06
ABP - Advancing Brigatinib Properties in anaplastic lymphoma kinase positive nonsmall cell lung cancer (ALK+ NSCLC) patients by deep phenoty… Ended

2024-513947-94-00 locally advanced (stage III) and not suitable for curat 4 2020-03-30
Phase 1/2 Study of CLN-081 in Patients with Lung Cancer Ended

2024-516532-97-00 Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Inser 9 2020-03-26
Phase III study of Pembrolizumab plus chemoradiation vs chemoradiation along for patients with muscle invasive bladder cancer Ended

2023-503500-87-00 Muscle Invasive Bladder Cancer 11 2020-03-17
Short course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined… Ended

2024-511577-29-01 intermediate and high-risk rectal cancer 5 2020-03-13
A Phase 3 Trial Comparing Selpercatinib to Cabozantinib or Vandetanib in Patients with RET-Mutant Medullary Thyroid Cancer Ended

2023-506782-56-00 RET-Mutant Medullary Thyroid Cancer 5 2020-03-10
First-in-human study of ICT01 in patients with advanced-stage, relapsed/refractory cancer Ended

2024-515560-30-00 Advanced-stage, relapsed/refractory cancer 7 2020-03-05
A phase 1 study of GSK2857916 + Standard of Care (SOC) in first line multiple myeloma patients (DREAMM-9) Ended

2023-507060-39-00 Multiple Myeloma 3 2020-03-04
A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subj… Ended

2023-503468-17-00 Multiple myeloma 3 2020-03-02
IMMUWHY Ended

2023-508314-42-00 Advanced stage intrahepatic biliary tract cancer (BTC) 4 2020-02-27
A Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy with or without Pembrolizumab (LIBRETTO-431) Ended

2023-506783-14-00 Advanced or Metastatic RET Fusion-Positive Non-Small Ce 5 2020-02-24
Trastuzumab Deruxtecan, and pembrolizumab in participants with Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer Ended

2023-509866-39-00 Locally advanced/metastatic breast or non-small cell lu 3 2020-02-14
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma Ended

2024-511653-22-00 Cutaneous Squamous Cell Carcinoma (CSCC) 5 2020-02-12
A phase-2 academic trial testing, in two parallel non-randomized cohorts, the combination of ruxolitinib (JAK1/2 inhibitor) with brentuximab… Ended

2024-520123-83-01 Patients with relapsed or refractory cHL that has not r 4 2020-02-11
Immune induction strategies to improve response to immune checkpoint blockade in triple negative breast cancer (TNBC) patients: the TONIC-2 … Ended

2024-513217-12-00 Triple negative breast cancer (TNBC) with metastatic di 4 2020-02-04
Precision medicine phase II study evaluating the efficacy of a double immunotherapy by Durvalumab and Tremelimumab combined with Olaparib in… Ended

2024-518069-89-00 Patients with solid cancers 4 2020-02-03
Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiothera… Ended

2022-501973-37-00 Endometrial cancer 5 2020-01-30